| Literature DB >> 30024271 |
Barbara Błaszczyk1, Barbara Miziak2, Piotr Czuczwar2,3, Ewa Wierzchowska-Cioch2,4, Ryszard Pluta5, Stanisław J Czuczwar2,6.
Abstract
INTRODUCTION: Considering that there are around 30% of patients with epilepsy resistant to monotherapy, the use of synergistic combinations of antiepileptic drugs is of particular importance. This review shows most beneficial as well as irrational combined treatments both from an experimental and clinical point of view. Areas covered: Preferably, experimental data derived from studies evaluating synergy, additivity, or antagonism by relevant methods, in terms of anticonvulsant or neurotoxic effects and pharmacokinetic data have been considered. Although there have been no randomized clinical trials on this issue, the clinical data have been analyzed from studies on considerable numbers of patients. Case-report studies have been not considered. Expert commentary: The experimental data provide a strong support that co-administration of lamotrigine with carbamazepine is negative, considering the anticonvulsant and neurotoxic effects. Clinical reports do not entirely support this conclusion. Other experimentally documented negative combinations comprise lamotrigine+ oxcarbazepine and oxcarbazepine+ phenytoin. From the experimental and clinical point of view, a combination of lamotrigine+ valproate may deserve recommendation. Other most positive experimental and clinical combinations include carbamazepine+valproate, phenytoin+phenobarbital, carbamazepine+gabapentin, carbamazepine+topiramate, levetiracetam+valproate, levetiracetam+carbamazepine. Certainly, experimental data have some limitations (non-epileptic animals, acute administration of antiepileptic drugs) so all experimental recommendations need a careful clinical evaluation.Entities:
Keywords: Antiepileptic drugs; anticonvulsant; drug combinations; epilepsy; isobolography; neurotoxicity; seizures
Mesh:
Substances:
Year: 2018 PMID: 30024271 DOI: 10.1080/17512433.2018.1500895
Source DB: PubMed Journal: Expert Rev Clin Pharmacol ISSN: 1751-2433 Impact factor: 5.045